NEW YORK (360Dx) – Hørsholm, Denmark-based ExpreS2ion Biotech Holding said today that it its subsidiary ExpreS2ion Biotechnologies has entered a collaboration that gives Institut VirionSerion in Würzburg, Germany access to evaluate new in vitro diagnostic candidates produced using the ExpreS2 platform.
The collaboration also grants Virion commercial rights to promote, sell, and distribute protein antigens produced using the same platform.
Financial terms of the agreement were not disclosed. However, ExpreS2ion said that it expects to generate annual revenues in excess of €250,000 ($297,500) as a result of the agreements when the collaboration has been implemented.
As part of the collaboration, a material transfer agreement gives Virion rights to evaluate a number of undisclosed protein antigens produced by ExpreS2ion, with the purpose of making commercially available protein antigens. ExpreS2ion and Virion will discuss an agreement that ensures supply and commercialization conditions of the antigens, Expres2ion said.
A research and commercial license agreement between the two parties gives Virion research and commercial rights to develop and market proteins produced using the ExpreS2 technology. ExpreS2ion said that the agreement specifies an annual research license fee and a two-digit percentage royalty on net sales to be paid by Virion to ExpreS2ion.